Role of osteoprotegerin in the development of osteopenic syndrome in case of chronic obstructive lung disease

Written by Kochetkova E.A., Bourya K.A., Ugay L.G., Kotsyurbiy E.A., Nevzorova V.A., Lukiyanov P.A., Albavichus S.A.

  UDK: 616.71‑007.234‑06:616.24‑007.272‑036.2 | Pages: 20-22 | Full text PDF | Open PDF 


The medical observation of 55 patients aged 44‒58 years
old suffering from chronic obstructive lung disease has allowed to
study the relationship between the levels of osteoprotegerin, markers of
bone metabolism, tumour necrosis‑a factor in blood serum and bone
tissue mineral density. The Dual‑energy X‑ray absorptiometry was a
technique used to measure the bone tissue mineral density. All this al‑
lowed diagnosing the osteopenic syndrome in 43 cases and confirming
the direct correlation between the content of tumour necrosis‑a factor
and markers of bone resorption in blood serum, and between the con‑
tent of osteoprotegerin and bone tissue mineral density

Links to authors:

E.A. Kochetkova, K.A. Bourya, L.G. Ugay, E.A. Kotsyurbiy, V.A. Nevzorova, P.A. Lukiyanov, S.A. Albavichus
E.A. Kochetkova, K.A. Bourya, L.G. Ugay, E.A. Kotsyurbiy, V.A. Nevzorova, S.A. Albavichus
Vladivostok State Medical University (2 Ostryakova Av. Vladivostok 690950 Russian Federation)
P.A. Lukiyanov
Pacific Institute of Bioorganic Chemistry of the FEB RAS (159 100th Anniversary of Vladivostok Av. Vladivostok 690022 Russian Federation)

  1. 1.Kochetkova E.A., Volkova M.V., Gelcer B.I. Cytokine status in
    patients with chronic obstructive pulmonary disease and its re‑
    lationship to the functional state of bone tissue // Archive. 2004.
    Vol. 76, No. 3. P. 23–27.
    2. Biskobing D.M. COPD and osteoporosis // Chest. 2002. Vol. 121,
    No. 2. P. 609–620.
    3. Bolton C.E., Ionescu A.A., Shiels K.M. et al. Associated loss
    fat‑free mass and bone mineral density in chronic obstructive
    pulmonary disease // Am. J. Respir. Crit. Care Med. 2004. Vol.
    170, No. 12. P. 1286–1293.
    4. Dougall W.C., Chaisson M. The RANKL/RANK/OPG triad in
    cancer‑induced bone diseases // Cancer Metastasis Rev. 2006.
    Vol. 25, No. 4. P. 541–549.
    5.Hofbauer L.C., Khosla S., Dunstan C.R. et al. The role of osteopro‑
    tegerin and osteoprotegerin ligand in the paracrine regulation of
    bone resorption // J. Bone Miner. Res. 2000. Vol. 15, No. 1. P. 2–12.
    6.Incalzi R.A., Caradonna P., Ranieri P. et al. Correlates of osteo‑
    porosis in chronic obstructive pulmonary disease // Respir. Med.
    2000. Vol. 94, No. 11. P. 1079–1084.
    7. Mezquita‑Raya P., Higuera M., Garcia D.F. et al. The contribution
    of serum osteoprotegerin to bone mass and vertebral fractures
    in postmenopausal women // Osteoporosis Int. 2005. Vol. 16,
    No. 11. P. 1368–1374.
    8. Monegal A., Navasa M., Peris P. et al. Serum osteoprotegerin
    and its ligand in cirrhotic patients referred for osteoporotic liver
    transplantation: relationship with metabolic bone disease // Liver
    international. 2007. Vol. 27, No. 4. P. 492–497.
    9. Pennisi P., Signorelli S.S., Ricobene S. et al. Low bone density and
    abnormal in patients with atherosclerosis of peripheral vessels //
    Osteoporosis Int. 2004 Vol. 15, No. 5. P. 389–395.
    10.Rogers A., Saleh G., Hannon R.A. et al. Circulating estradiol
    and osteoprotegerin as determinant of bone turnover and bone
    density in postmenopausal women // J. Clin. Endocrinol. Metab.
    2002. Vol. 87, No. 4. P. 4470–4475.
    11.Warren S., Browner W.S., Lui L.Y., Steven R. Associations of
    serum osteoprotegerin levels with diabetes, stroke, bone density,
    fractures, and mortality in elderly women // J. Clin. Endocrinol.
    Metab. 2001. Vol. 86, No. 4. P. 631–637. 


Founded in 1997  |  Editions in a year: 4, Articles in one issue: 30 |  ISSN of print version: 1609-1175  |  Ind.: 18410 (Agency "Rospechat’")  |  Edition: 1000 c.